| 公司介绍： |
Hancock Jaffe Laboratories, Inc. is a development stage medical device company developing biologic based solutions that are designed to be life-enhancing for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease, or ESRD. Each product candidate The company is developing is designed to allow vascular and cardiothoracic surgeons to achieve effectiveness while improving current procedures and healthcare for a variety of patients. The company is in the process of developing and obtaining U.S. Food and Drug Administration, or FDA, approval for the following three product candidates : the Bioprosthetic Heart Valve, which the comapany refers to as BHV, the Bioprosthetic Coronary Artery Bypass Graft, which the comapany refers to as CoreoGraft, and the Bioprosthetic Venous Valve, which the company refers to as the VenoValve. The company has previously manufactured, developed and obtained FDA pre-market approval for the ProCol Vascular Bioprosthesis, a product for hemodialysis vascular access in patients with ESRD, which the company sold to LeMaitre Vascular, Inc., or LMAT, in March 2016. |
